Hopp til hovedinnhold

Arteritis temporalis (AT)

Sist oppdatert: Sist revidert:
Sist revidert av:
Definisjon:
Arteritis temporalis er kjempecellevaskulitt i middelstore arterier, oftest i grener til arteria carotis. Ukjent årsak
Forekomst:
Ca. 25 per 100 000 per år. Vanligvis over 50 år. Særlig hyppig i Skandinavia
Symptomer:
Hovedsymptomer er ømhet i temporalregionen, allmennsymtpomer, tyggesmerter og synsforstyrrelser (dobbeltsyn, tåkesyn eller forbigående blindhet). 
Funn:
Lokalisert ømhet i en fortykket temporalarterie
Diagnostikk:
Forhøyet SR. Fortykket temporalarterie ved ultralyd. Diagnose bekreftes ved temporalisbiopsi. 
Behandling:
Kortikosteroider. Høydosert initialt, gradvis nedtrapping. Osteoporoseprofylakse. 
  1. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002; 347: 261-71. PubMed  
  2. Caylor TL, Perkins A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. Am Fam Physician 2013; 88: 676-84. American Family Physician  
  3. Soriano A, Verrecchia E, Marinaro A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of literature. Lupus 2012; 21: 153-7. PubMed  
  4. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010; 49: 186-90. Rheumatology  
  5. Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9. New England Journal of Medicine  
  6. Duhaut P, Bosshard S and Ducroix J-P. Is giant cell arteritis and infectious disease? Biological and epidemiological evidence. Presse Med 2004; 33: 1403-8. PubMed  
  7. Gilden D, White T, Khmeleva N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 2015. DOI: 10.1212/WNL.0000000000001409 DOI  
  8. Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum 2004; 33: 294-301. PubMed  
  9. Ezeonyeji AN, Borg FA, Dasgupta B. Delays in recognition and management of giant cell arteritis: results from a retrospective audit. Clin Rheumatol. 2011;30(2):259–262.
  10. Unwin B, Williams CN, Gilliland W. Polymyalgia rheumatica and giant cell arteritis. Am Fam Physician 2006; 74: 1547-54. PubMed  
  11. van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020. PMID: 32804186 PubMed  
  12. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372: 234-45. PubMed  
  13. Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A and Llorca J. Giant cell arteriris: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005; 84: 269-76. PubMed  
  14. Salvarani C, Cimino L, Macchioni PL et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 2005; 53: 293-7. PubMed  
  15. Singh AG, Kermani TA, Crowson CS, et al. Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. J Rheumatol. 2015 Feb;42(2):309-15. PubMed  
  16. Salvarani C and Hunder GG. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 1999; 42: 1259-66. PubMed  
  17. Coronel L, Rodríguez-Pardo J, Monjo I, de Miguel E. Prevalence and significance of ischemic cerebrovascular events in giant cell arteritis. Med Clin (Barc). 2021 Jul 23;157(2):53-57. English, Spanish. PMID: 32826078 PubMed  
  18. de Boysson H, Liozon E, Larivière D, et al. Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study. J Rheumatol. 2017 Mar;44(3):297-303. Epub 2017 Jan 15. PMID: 28089985 PubMed  
  19. Salvarini C, Muratore F. Clinical manifestations of giant cell arteritis. UpToDate. Sist oppdatert 23.05.2022. Siden lest 15.11.2022. www.uptodate.com  
  20. Gran JT, Myklebust G. Incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis. Rheumatology 2000; 39: 283-7. Rheumatology  
  21. Haga HJ, Johnsen V, Østensen M, Mikkelsen K, Gulseth HC, Kvien TK, Nordvåg BY. Myalgi og høy senkning hos voksne. Tidsskr Nor Lægeforen 2000; 120: 3405-8. Tidsskrift for Den norske legeforening  
  22. Dasgupta B, Cimmino MA, Maradit-Kremers H et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012; 65: 943-54. PubMed  
  23. Caselli RJ, Hunder GG. Giant cell (temporal) arteritis. Neurologic Clinics 1997; 15: 893-902. PubMed  
  24. Schmidt D, Vaith P, Hetzel A. Prevention of serious ophthalmic and cerebral complications in temporalis arteritis? Clin Exp Rhematol 2000; 18: 61-3. PubMed  
  25. Frearson R, Cassidy T, Newton J. Polymyalgia rheumatica and temporal arteritis: evidence and guidelines for diagnosis and management in older people. Age Ageing 2003; 32: 370-4. PubMed  
  26. Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol 2004; 16: 25-30. PubMed  
  27. Hunder GG. Treatment of giant cell (temporal) arteritis. UpToDate, last updated Aug 17, 2017. www.uptodate.com  
  28. Warrington KJ, Matteson EL. Giant cell arteritis. BMJ Best Practice, last updated Nov 2017. bestpractice.bmj.com  
  29. Hayreh SS, Zimmermann B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80: 355-71. PubMed  
  30. Pipitone N and Salvarani C. Are steroids alone sufficient for the treatment of giant cell arteritis?. Best Pract Res Clin Rheumatol 2005; 19: 277-92. PubMed  
  31. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015 Oct;74(10):1799-807. PubMed  
  32. Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016 Oct 5;10:CD001347. pmid: 27706804 PubMed  
  33. Rosen HN, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. UpToDate. Sist revidert juni 2015. www.uptodate.com  
  34. NICE Guidance. Tocilizumab for treating giant cell arteritis. Technology appraisal guidance [TA518] - 2018. www.nice.org.uk  
  35. Øverlie H, Kerty E. Temporalisarteritt og cerebrovaskulære komplikasjoner. Tidsskr Nor Lægeforen 2005; 125: 2936-8. PubMed  
  36. Nesher G, Berkun Y, Mates M et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine 2004; 83: 114-22. PubMed  
  37. Nesher G, Berkun Y, Mates M et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332-7. PubMed  
  38. Mollan SP, Sharrack N,Burdon MA, et al. Aspirin as adjunctive treatment for giant cell arteritis. Cochrane Database Syst Rev. 2014 ;8:CD010453. DOI: 10.1002/14651858.CD010453.pub2. DOI  
  39. Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease relapses among patients with giant cell arteritis: A prospective, longitudinal cohort study. J Rheumatol 2015; 42:1213. doi: 10.3899/jrheum.141347 DOI  
  40. Faurschou M, Ahlstrom MG, Lindhardsen J, et al. Risk of Diabetes mellitus among patients diagnosed with giant cell arteritis or granulomatosis with polyangiitis: Comparison with the general population. J Rheumatol. 2016 . PMID:27744394 PubMed  
  41. Pujades-Rodriguez M, Duyx B, Thomas SL, et al. Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. Heart 2016. doi:10.1136/heartjnl-2015-308514 DOI  
  • Terje Johannessen, professor i allmennmedisin, Trondheim (tilpasning til NEL)

Tidligere fagmedarbeidere

  • Gunnar Husby, professor i revmatologi, Oslo Sanitetsforenings Revmatismesykehus, Universitetet i Oslo og Rikshospitalet, Oslo